USFDA completes pre-approval inspection at Laurus Labs’ facility in Andhra Pradesh

29 Oct 2022 Evaluate

US Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) at Laurus Labs’ manufacturing facility at Unit-5, Parawada, Visakhapatnam, Andhra Pradesh. The inspection was conducted from October 24, 2022 to October 28, 2022. The company has been issued a Form 483 with one observation. The observation is procedural in nature. The company will address the observation within stipulated timelines.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

586.40 15.60 (2.73%)
27-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1861.70
Dr. Reddys Lab 1389.35
Cipla 1506.15
Lupin 2228.00
Zydus Lifesciences 972.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.